Last reviewed · How we verify
Mundipharma K.K. — Portfolio Competitive Intelligence Brief
1 marketed
0 filed
1 Phase 3
0 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Buprenorphine Transdermal System | Buprenorphine Transdermal System | marketed | ||||
| Pralatrexate injection | Pralatrexate injection | phase 3 | Antifolate antimetabolite | Dihydrofolate reductase (DHFR), folate receptor, reduced folate carrier | Oncology |
Therapeutic area mix
- Oncology · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Allist Pharmaceuticals, Inc. · 1 shared drug class
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · 1 shared drug class
- Radboud University Medical Center · 1 shared drug class
- Shanghai Miracogen Inc. · 1 shared drug class
- The First Affiliated Hospital with Nanjing Medical University · 1 shared drug class
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Mundipharma K.K.:
- Mundipharma K.K. pipeline updates — RSS
- Mundipharma K.K. pipeline updates — Atom
- Mundipharma K.K. pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Mundipharma K.K. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/mundipharma-k-k. Accessed 2026-05-16.